Virus-like particle (VLP) is a polymeric nanostructure assembled from natural viral structural proteins, but do not contain any genetic material. The VLP consists of high-density displays of viral surface proteins and is therefore a highly adaptable tool for a variety of applications, such as delivery system, antibody development, and membrane protein expression. During the coronavirus pandemic, Creative Biostructure rapidly integrated VLP-based vaccine development technologies and various in-house coronavirus-related VLP products to facilitate the development of methods for the prevention of this emerging infectious disease.
Traditional vaccines are prepared with attenuated or inactivated virus strains, however, VLPs lacking viral genomes can offer a much safer option. VLPs are similar in structure to real viruses and do not contain any viral genetic material, thus they are not infectious and have the potential to trigger a powerful immune response. VLP-based vaccines are one of the emerging vaccine technologies that produce effective and durable protection. VLP provides a multivalent structure that can hold multiple copies of antigens and can elicit a more effective immune response. VLPs can also ensure tissue-specific targeting because they are derived from real viruses. These versatile and stable nanoparticles show great adjuvant properties and can induce innate immune responses. They can present both B-cell epitopes for antibody production and T-cell epitopes for inducing effective cellular immune responses. To date, several VLP-based vaccines have been licensed and commercialized, and many are in clinical trials.
Figure 1. Immunogenic features of a virus-like particle (VLP). (Crisci E.; et al. 2013)
Nowadays, for the SARS-CoV-2 infection, Creative Biostructure offers high-quality VLP-based vaccine development services to customers in the academia, biotech/pharmaceutical industries around the world.
Our professional team has mastered a variety of VLP expression systems, including but not limited to yeast, baculovirus expression system, and mammalian cells. We can design and develop custom VLPs, and our off-the-shelf VLP products have been shown to present antigenic epitopes in their appropriate conformation to induce effective humoral and cellular immune responses. In addition, we offer a variety of in-house developed VLP products of the family Coronaviridae.
Creative Biostructure specializes in the formulation and innovation of VLP-based vaccines. We utilized the most commonly used adjuvant aluminum salts in VLP-based vaccine formulations to enhance the immunogenicity of antigens. And we have made great efforts in the innovative development of VLP-based vaccines, such as reducing the antigen dose, improving the immunogenicity, and improving the stability of long-term storage.
If your coronavirus vaccine development project involves VLP technology, please do not hesitate to contact us, our customer service representatives are available 24 hours a day from Monday to Sunday. Our experienced scientists will work closely with you to keep you informed of the progress of the project and take all the objectives into consideration.